Royalty Pharma plc Proceeds from Interest Received
Royalty Pharma plc (RPRX) reported Proceeds from Interest Received of $11.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromInterestReceived · last filed 2026-08-05
- Royalty Pharma plc proceeds from interest received for the quarter ending 2026-06-30 was $4.98M, a 42.54% decline year-over-year.
- Royalty Pharma plc proceeds from interest received for the quarter ending 2026-03-31 was $6.50M, a 45.97% decline year-over-year.
- Royalty Pharma plc proceeds from interest received for the quarter ending 2025-12-31 was $6.37M, a 29.46% decline year-over-year.
- Royalty Pharma plc proceeds from interest received for the quarter ending 2025-09-30 was $7.25M, a 56.16% decline year-over-year.
- Royalty Pharma plc proceeds from interest received for fiscal 2025 was $34.31M, a 26.19% decline from fiscal 2024.
- Royalty Pharma plc proceeds from interest received for fiscal 2024 was $46.48M, a 35.08% decline from fiscal 2023.
- Royalty Pharma plc proceeds from interest received for fiscal 2023 was $71.60M, a 186.62% increase from fiscal 2022.
- Royalty Pharma plc proceeds from interest received for fiscal 2022 was $24.98M, a 696.87% increase from fiscal 2021.
| Period end | Proceeds from Interest Received 3 month | Proceeds from Interest Received 6 month | Proceeds from Interest Received 9 month | Proceeds from Interest Received 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $11.47M 10-Q · filed 2026-08-05 | $17.85M derived: sum of 3 quarters · filed 2026-08-05 | $25.09M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $6.50M 10-Q · filed 2026-05-06 | $12.87M derived: sum of 2 quarters · filed 2026-05-06 | $20.12M derived: sum of 3 quarters · filed 2026-05-06 | $28.78M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $6.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $13.62M derived: sum of 2 quarters · filed 2026-02-11 | $22.28M derived: sum of 3 quarters · filed 2026-08-05 | $34.31M 10-K · filed 2026-02-11 |
| 2025-09-30 | $7.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $15.91M derived: sum of 2 quarters · filed 2026-08-05 | $27.93M 10-Q · filed 2025-11-05 | $36.97M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $8.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $20.69M 10-Q · filed 2026-08-05 | $29.72M derived: sum of 3 quarters · filed 2026-08-05 | $46.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $12.03M 10-Q · filed 2026-05-06 | $21.06M derived: sum of 2 quarters · filed 2026-05-06 | $37.59M derived: sum of 3 quarters · filed 2026-05-06 | $52.08M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $9.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $25.57M derived: sum of 2 quarters · filed 2026-02-11 | $40.05M derived: sum of 3 quarters · filed 2026-02-11 | $46.48M 10-K · filed 2026-02-11 |
| 2024-09-30 | $16.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $31.02M derived: sum of 2 quarters · filed 2025-11-05 | $37.45M 10-Q · filed 2025-11-05 | $45.92M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $14.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $20.91M 10-Q · filed 2025-08-06 | $29.38M derived: sum of 3 quarters · filed 2026-02-11 | $58.01M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $6.43M 10-Q · filed 2025-05-08 | $14.90M derived: sum of 2 quarters · filed 2026-02-11 | $43.52M derived: sum of 3 quarters · filed 2026-02-11 | $62.47M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $8.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $37.09M derived: sum of 2 quarters · filed 2026-02-11 | $56.04M derived: sum of 3 quarters · filed 2026-02-11 | $71.60M 10-K · filed 2026-02-11 |
| 2023-09-30 | $28.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $47.57M derived: sum of 2 quarters · filed 2024-11-06 | $63.13M 10-Q · filed 2024-11-06 | $77.56M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $18.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $34.51M 10-Q · filed 2024-08-08 | $48.94M derived: sum of 3 quarters · filed 2025-02-12 | $56.23M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $15.57M 10-Q · filed 2024-05-09 | $29.99M derived: sum of 2 quarters · filed 2025-02-12 | $37.29M derived: sum of 3 quarters · filed 2025-02-12 | $40.07M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $14.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $21.72M derived: sum of 2 quarters · filed 2025-02-12 | $24.50M derived: sum of 3 quarters · filed 2025-02-12 | $24.98M 10-K · filed 2025-02-12 |
| 2022-09-30 | $7.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $10.07M derived: sum of 2 quarters · filed 2023-11-08 | $10.56M 10-Q · filed 2023-11-08 | $10.69M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $2.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $3.26M 10-Q · filed 2023-08-08 | $3.39M derived: sum of 3 quarters · filed 2024-02-15 | $4.07M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $482.00K 10-Q · filed 2023-05-09 | $613.00K derived: sum of 2 quarters · filed 2024-02-15 | $1.28M derived: sum of 3 quarters · filed 2024-02-15 | $2.07M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $131.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $803.00K derived: sum of 2 quarters · filed 2024-02-15 | $1.59M derived: sum of 3 quarters · filed 2024-02-15 | $3.13M 10-K · filed 2024-02-15 |
| 2021-09-30 | $672.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.46M derived: sum of 2 quarters · filed 2022-11-08 | $3.00M 10-Q · filed 2022-11-08 | $3.23M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $784.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $2.33M 10-Q · filed 2022-08-04 | $2.56M derived: sum of 3 quarters · filed 2023-02-15 | $6.44M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $1.55M 10-Q · filed 2022-05-05 | $1.78M derived: sum of 2 quarters · filed 2023-02-15 | $5.66M derived: sum of 3 quarters · filed 2023-02-15 | $7.02M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $228.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $4.11M derived: sum of 2 quarters · filed 2023-02-15 | $5.47M derived: sum of 3 quarters · filed 2023-02-15 | $7.70M 10-K · filed 2023-02-15 |
| 2020-09-30 | $3.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $5.24M derived: sum of 2 quarters · filed 2021-11-10 | $7.48M 10-Q · filed 2021-11-10 | $9.35M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $3.60M 10-Q · filed 2021-08-11 | $5.47M derived: sum of 3 quarters · filed 2022-02-15 | $9.28M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $2.24M 10-Q · filed 2021-05-11 | $4.11M derived: sum of 2 quarters · filed 2022-02-15 | $7.91M derived: sum of 3 quarters · filed 2022-02-15 | |
| 2019-12-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $5.68M derived: sum of 2 quarters · filed 2022-02-15 | $20.14M 10-K · filed 2022-02-15 | |
| 2019-09-30 | $3.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $18.26M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $14.46M 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $24.44M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |